Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,996 people get GERN articles and Market Currents by email alert.
Get email alerts on GERN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Geron Management Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 30, 2012 • 1 Comment
-
-
-
-
-
-
-
-
-
-
-
-
-
Geron Q2 Results: Net Loss of $21.1 MillionHenry McCusker • Mon, Aug 1, 2011
-
-
-
-
-
-
-
-
Geron Management Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 30, 2012 • 1 Comment
-
Geron Management Discusses Q2 2012 Results - Earnings Call TranscriptTue, Jul 31, 2012 • 1 Comment
-
Geron CEO Discusses Q3 2010 Results - Earnings Call TranscriptSat, Oct 30, 2010 • 2 Comments
-
Geron Corporation Q2 2010 Earnings Call TranscriptSat, Jul 31, 2010
-
Geron Corporation Q1 2010 Earnings Call TranscriptSun, Jun 13, 2010 • 7 Comments
-
Geron Corporation Q1 2008 Earnings Call TranscriptFri, May 30, 2008
-
Geron Corporation Q4 2007 Earnings Call TranscriptMon, Mar 17, 2008 • 2 Comments
-
at CNBC.com (Jan 17, 2013)
-
at MarketWatch.com (Dec 3, 2012)
-
at CNBC.com (Dec 3, 2012)
-
at MarketWatch.com (Sep 10, 2012)
-
at CNBC.com (Sep 10, 2012)
-
at MarketWatch.com (Aug 30, 2012)
-
at MarketWatch.com (Aug 30, 2012)
-
Business Wire (Dec 12, 2011)
-
at MarketWatch.com (Nov 15, 2011)
-
at MarketWatch.com (Sep 30, 2011)
-
at MarketWatch.com (Jul 13, 2011)
-
at MarketWatch.com (Jul 8, 2011)
-
at MarketWatch.com (Jul 8, 2011)
-
at CNBC.com (Jun 27, 2011)
-
at MarketWatch.com (May 2, 2011)
-
at MarketWatch.com (Mar 14, 2011)
-
at CNBC.com (Jan 26, 2011)
-
at MarketWatch.com (Dec 7, 2010)
-
at MarketWatch.com (Dec 7, 2010)
-
at MarketWatch.com (Oct 11, 2010)
GERN vs. ETF Alternatives
Company Description
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, April 26, 10:48 AM Geron (GERN -5%) slips after posting a mixed Q1 report late yesterday that came up short on its bottom line. The company also announced plans to cut its workforce by about a third and discontinue its discovery research and companion diagnostics programs, as the pharmaceutical company plans to put its entire focus on the development of Imetelstat, a treatment for hematologic myeloid malignancies. 1 Comment [Healthcare, On the Move, Earnings]
- Thursday, April 25, 5:04 PM Geron (GERN): Q1 EPS loss of $0.09 misses by $0.01. Revenue of $765M beats by $55M. (PR). Comment! [Healthcare, Earnings, Breaking News]
- Thursday, April 25, 12:10 AM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
- Wednesday, April 24, 5:35 PM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
- Tuesday, April 9, 9:33 AM Geron (GERN -4.3%) looks like it will be unable to use its imetelstat drug for treating lung-cancer patients after final results from a Phase II study confirm that the medicine was ineffective in a sub-group of patients in which initial results had looked promising. (PR) 1 Comment [Healthcare]
- Thursday, March 14, 10:49 AM Shares of Geron (GERN -6.1%) get slammed today, despite posting a solid Q4 report after yesterday's close. Revenues soared by nearly 175% from the prior year period, easily topping consensus estimates. However, concerns over an ongoing investigation into lab value abnormalities from its essential thrombocythemia study, plus opaque visibility on imetelstat progress have prompted a number of firms to cut their ratings. Piper Jaffray downgraded the shares to Overweight, while mid-day yesterday Stifel Nicolaus went even further, cutting the shares to sell. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, March 12, 5:07 PM Geron (GERN): Q4 EPS of -$0.12 beats by $0.02. Revenue of $689K beats by $189K. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, March 12, 12:10 AM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT Comment! [Earnings]
- Monday, March 11, 5:35 PM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT 2 Comments [Earnings]
- Friday, January 18, 9:17 AM Geron (GERN) +5.4% after an upgrade to Buy with $3 price target by Piper Jaffray's Charles Duncan. The current price of $1.66 reflects past challenges, he says, but leaves room for substantial upside over the course of the next year. That Geron and INO are buys at Piper while ZIOT and THLD are Holds does not compute, says Dan Rosenblum. Sell-side games, says TheStreet's Adam Feuerstein. 1 Comment [Healthcare, On the Move]
-
Friday, January 18, 9:10 AM
Premarket gainers: PATH +16%. LIFE +12%. NEWL +8%. RIMM +8%. MS +7%. SNE +7%. GERN +5%.
Losers: FNSR -10%. TSRX -9%. WIT -8%. COF -7%. INTC -6%.
2 Comments [On the Move] - Monday, January 7, 1:15 PM Shares of Geron (GERN +2.5%) snd BioTime (BTX +7.6%) both rise today after BTX agrees to buy the intellectual property, including patents and patent applications, and other assets related to GERN's human embryonic stem cell programs. The financial terms of the deal were in a letter of intent announced back in mid-November. Comment! [Healthcare, M&A, On the Move]
-
Monday, December 10, 2012, 12:45 PM
Midday top 10 gainers: CBMX +37%. UNXL +37%. ACUR +32%. GERN +25%. IN +23%. CLDX +23%. GPRC +20%. TELK +19%. SUMR +17%. EJ +16%.
Midday top 10 Losers: ZGNX -47%. CSFS -25%. MEAD -13%. TCCO -12%. GTIM -11%. SEV -10%. GEO -10%. BLIN -10%. DCTH -9%. NQ -9%. Comment! [On the Move] - Monday, December 10, 2012, 9:34 AM Geron (GERN) soars 15.1% after saying that its imetelstat treatment performed well in Phase II trials of patients with a chronic blood disorder called essential thrombocythemia. Geron designed the trial to provide a proof of concept for the potential use of imetelstat to treat blood cancers. Geron shares were slammed last week after it said it was stopping the development of therapies for brain cancer. (Presentation) 1 Comment [Healthcare]
-
Monday, December 10, 2012, 9:10 AM
Premarket gainers: IN +23%. GERN +17%. NXY +15%. CLDX +10%. STSI +7%. AAV +7%.
Losers: ZGNX -39%. CBMX -18%. DMND -5%. Comment! [On the Move] -
Tuesday, December 4, 2012, 12:45 PM
Midday top 10 gainers: ALDA +54%. SINO +29%. CYCC +17%. LTBR +12%. CORT +12%. SAB +11%. EDMC +10%. CPGI +11%. PRIS +10%. ACLS +10%.
Midday top 10 Losers: UEPS -56%. GERN -24%. EXA -22%. CUR -20%. SSN -19%. PPHM -16%. IQNT -18%. PBY -14%. GURE -12%. LEDS -12%. 3 Comments [On the Move]
-
Gainz Burger
$GERN- any thoughts on earnings results and data? Looks like they will distribute stock and/ or cash one Biotime deal is completed- - View all 0 replies
-
John Motyka
$GERN: Traces Bloodline back to "the horse 'can do!'" One shot left. Do something upsetting and 'breakthough'. Do this & pull the Upset..jdm - View all 0 replies
-
- View all 0 replies
-
John Motyka
Longshots include ARCI, GERN, MAKO and MITK. Study up and lay your bets down on their futures...jdm - View all 6 replies
-
FortSumter: John - I do not. From what I understand MAKO is mainly in the west? Is there anybody else besides ISRG that does what they do? -
John Motyka: Sumter: Some big boys working on prototypes, but ISRG first to market. The $ for these systems is in hardware and commissions per procedure.
-
Asif Suria
BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation $GERN $BTX http://bit.ly/Ty8eci - View all 0 replies
-
John Motyka
das: Better think some more about GERN. This one has been a heartbreaker in the past. I continue to Hold GERN and watch...jdm - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
John Motyka
Techies: Explain GERN recent chart action. Price appreciation+Volume uptrend+SMA crossing = -50% share value! Didnot see it coming. Why? jdm - View all 3 replies
-
John Motyka: Technical analysis is in the eye of the beholder. How could such a promising chart be so empty of predictive value?...jdm
-
LATEST REPLIES
-
John Motyka
Longshots include ARCI, GERN, MAKO and MITK. Study up and lay your bets down on their futures...jdm - View all 6 replies
-
FortSumter: John - I do not. From what I understand MAKO is mainly in the west? Is there anybody else besides ISRG that does what they do?
-
John Motyka: Sumter: Some big boys working on prototypes, but ISRG first to market. The $ for these systems is in hardware and commissions per procedure.
-
John Motyka
Techies: Explain GERN recent chart action. Price appreciation+Volume uptrend+SMA crossing = -50% share value! Didnot see it coming. Why? jdm - View all 3 replies
-
John Motyka: Technical analysis is in the eye of the beholder. How could such a promising chart be so empty of predictive value?...jdm
-
-
iadops40
GERN also reporting disapointing phase 2 study of imetelstat, shares down -48% pre-market http://seekingalpha.com/n/bci5 - View all 1 replies
-
-
- View all 3 replies
-
-
TruffelPig: EXEL will have a product soon on the market - GERN after xxxxxxxxx years Phase II again.........
-
- View all 8 replies
-
Ocean Man: Something afoot means something happening, something amiss means something not right.
-
John Motyka: GERN: Price action last 6-8wks suggests "Sugar Daddy" w/ private money is providing downside support level. Cancer Tx may be in the news.jdm
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 4 replies
-
TruffelPig: Second half of this year should bring catalysts; let us hope in a good way
-
Gainz Burger: Im with you TP- have owned GERN for years now and am underwater. Pipeline is extensive & they are a good takeover candidate from big Pharma
-
John Motyka
GERN: Beats but still bleeds out. Patents and Phase III trail will tell the tale's outcome. Soon I hope. Nice entry point. Hold & Hope...jdm - View all 6 replies
-
-
John Motyka: GERN found a 'Sugar Daddy'. Could be frontrunner to next quarterly progress report. These new Cancer Tx's better be plenty Good...jdm
-
- View all 8 replies
-
-
John Motyka: X7 Volume holds onto gains. Hedge guy or Private Monies or Banker or Believer in GERN coming back to play. I Hold and Wait for GERN...jdm
-
- View all 3 replies
-
John Motyka: Funk~ This could be the beginning of a feeding frenzy. Let's watch developments together and keep in touch...jdm
-
-
John Motyka
DAG~Very quite. Earnings report for GERN 03/07/12. Beat est but still bleeding out. Firestorm ahead for Phase III. I continue to Hold...jdm - View all 18 replies
-
-
-
- View all 14 replies
-
DAG1996: lol no way in heck i'd buy a tiny biotech priced higher than most of the major pharmas. $50 is a sell price for a biotech, not a buy.
-
-
- View all 1 replies
-
-
- View all 3 replies
-
-
John Motyka: Noreika: SA has some articles about ARCI. Recycling patents, contracts w/ electric and actual earnings. Sharks circling on GERN & ALU...jdm